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Background: Based on data from the population-based Qidong Cancer Registry, we report a survival analysis for
female breast cancer patients diagnosed during 1972–2011 in order to assess the long-term trends for the prognosis
of this cancer.
Methods: The last follow-up for survival status of the 3,398 registered female breast cancer cases was April, 2012.
Cumulative observed survival (OS) and relative survival (RS) rates were calculated using Hakulinen’s method performed
by the SURV3.01 Software developed at the Finnish Cancer Registry.
Results: The one-, three-, five-, ten-, fifteen-, twenty-, thirty-, and forty- year OS rates were 83.61%, 67.53%, 58.75%,
48.56%, 42.57%, 38.30%, 29.19%, 19.35%; and the RS rates were 84.76%, 70.45%, 63.12%, 56.81%, 55.26%, 56.36%, 62.59%,
84.00%, respectively. Five-year RS rates of age groups 15–34, 35–44, 45–54, 55–64, 65–74, and 75+ were 60.17%,
68.27%, 67.79%, 56.03%, 55.50%, and 57.28%; 10-year RS rates were 54.16%, 59.59%, 61.34%, 47.78%, 51.30%, and
59.28%, respectively. There were statistical differences among the age groups (RS: χ2 = 152.15, P = 0.000). Remarkable
improvement could be seen for the 5-year RS rates from 52.08% in 1972 to 69.26% in 2003–2007, and the 10-year RS
rates from 43.16% in 1972 to 60.85% in 1998–2002, respectively.
Conclusions: Survival outcomes from Qidong registered cases with breast cancer have shown gradual progress during
the past 40 years. The disparities between survival rates of this area and developed countries are getting narrower, but
there is still great need for improving survival in Qidong.
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This study was based on the data of the Qidong Cancer
Registry (QCR), a population-based cancer registry,
which was established in 1972 and is administered by
the Qidong Liver Cancer Institute (QDLCI). The QCR
covers Qidong City, Jiangsu Province, China with an
area of 1208 km2, and a population of 1.12 M at the end
of 2011. Geographically, Qidong is located at the mouth
of the Yangtze River (Chang Jiang), by the Yellow Sea
(Huang Hai). The QCR is one of the longest standing
cancer registries in China. In 1974, the QDLCI established
an all-death cause registration system (as an official Vital
Statistics source) in the same coverage area for disease
monitoring.* Correspondence: chenjg@vip.sina.com
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unless otherwise stated.Breast cancer is now the most common cancer in
females all over the world [1,2]. With the development of
the economy and the improvement of living standards,
the incidence of breast cancer is increasing year by
year in China [3]. In Qidong, breast cancer has been
the fourth most common cancer in females over the
past 40 years, with an aggregate crude incidence rate
of 14.94 per 100 000, accounting for 9.95% of all cancer
sites combined in women. The annual percentage change
(APC) of the world age-standardized incidence rate be-
tween 1972 and 2011 was 1.31%, with a rapid increase
during the latter stages of the past four decades [4]. Thus,
further research on breast cancer etiology, prevention and
treatment hence is necessary.
This study presents current survival data and their
trends during the period of 1972–2011. The data collected
over this long-term period and the results accurately
derived from them reflect a profile for the prevalence and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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information on survival provides clinicians and researchers
with opportunities to explore breast cancer trends, to
measure progress against breast cancer, and to examine
implications for breast cancer control in the context of
associations with risk factors, prevention interventions,
and the dissemination of advances in treatment.
Methods
The data in this study are from the QCR, which at its
founding was designated as the cancer registration
repository by the local health authority with compulsory
reporting by health care workers. Several years later
cancer registration was mandated to be compulsory by
the provincial health authority. Now this cancer registry
is a member of the national monitoring program (or
the National Cancer Registration Network) [5,6] of
the National Central Cancer Registries of China sup-
ported by the Ministry of Finance and the Ministry of
Health of China: Tumor Follow-up Registration Programs
(MF2008-293, 2009–193, and 2010–90).
The Qidong All-death Cause Registration System has
been an official vital statistics source approved by the
Ministry of Health of China since 1974 [7], with death
from any cause reported by death certification notifica-
tions (DCN). Meeting International Agency for Research
on Cancer/International Association of Cancer Registries
(IARC/IACR) standards for quality, completeness, timeli-
ness and unresolved duplicate records, the QCR is a mem-
ber of the IACR. QCR data have been included in “Cancer
Incidence in Five Continents” (CI5) [8,9] and other publi-
cations [10-13]. The data reliability has earned recognition
in domestic and international studies [10,12,14]. For the
use of these cancer statistics, there is no further need for
approval by an Institutional Review Board and no need for
informed consent from any of the patients involved.
The QCR uses both active and passive methods for
cancer data collection. All data files received from
lower-level registries and all other hospitals are checked
with cancer report lists and DCNs in order to track
down missing cases and to exclude duplicate registra-
tions. At present, there are 12 town-level registries, each
with one full-time or part-time health worker doing the
registration and collection of DCNs. All new cancer
patients in the catchment area are therefore registered,
checked, and then reported to the QCR. When the
patient dies, whether at home or in hospital, the registra-
tion official adds the date of death to the record, and
reports it again, together with a DCN card. If the regis-
try personnel receive the death notification first, the
patient’s medical records are reviewed or a home visit is
carried out to obtain further information. Hence, the
collection of high-quality follow-up data has been
possible in Qidong [10,11].According to Union for International Cancer Control
(UICC), breast cancer refers to the malignant tumor
originating in the mammary gland epithelial tissue. In
QCR, cancer cases were classified and coded according
to the International Classification of Diseases, the 10th
revision (ICD-10), and the International Classification of
Diseases for Oncology 3rd edition [15] as well. This study
included all patients with female breast cancer reported to
the QCR from 1972 to 2011; codes of ICD-10 C50.0-C50.9
and topography codes C50.0-C50.9 of ICD-O-3 with
behaviour codes 3 were included. Excluded were all death
certificate-only, autopsy, and individual cases with malig-
nant secondary (metastatic to the breast), benign, in situ
and uncertain or unknown diagnosis.
A total of 3,452 cases with breast cancer were registered
from January 1, 1972 to December 31, 2011. Fifty-four
(1.56%) male breast cancer cases were excluded, hence
3,398 female breast cancers were included for analysis.
The deadline for the last follow-up for survival status was
April, 2012. The proportion of cases with morphological
verification was 93.11% (3,164/3,398), with no breast
cancer cases recognized by death certificate only. The
survival duration of each case was determined as the time
difference from the date of initial diagnosis to the date of
death due to breast cancer (1,687/3,398 = 49.65%), date of
death due to other diseases (3/3,398 = 0.09%), date of loss
to follow-up (381/3,398 = 11.21%), and the closing date for
those still alive (1,327/3,398 = 39.05%).
Cumulative observed survival (OS) and relative survival
(RS) rates were calculated. RS was defined as the ratio of
the OS rate to the expected rate, which was estimated
from the general gender and calendar period-specific life
tables for Qidong residents according to Hakulinen’s
method [16]. The survival experience of patients were
adjusted for normal life expectancy of the general
population of the same age, which makes RS rate an
estimate of the chance of surviving the effects of cancer
[17]. The OS and RS rates were computed within six age
groups (15–34, 35–44, 45–54, 55–64, 65–74, 75+) and
nine calendar periods (1972, 1973–1977, 1978–1982,
1983–1987, 1988–1992, 1993–1997, 1998–2002, 2003–
2007, 2008–2011), using Hakulinen’s method performed
by the SURV3.01 software developed at the Finnish Cancer
Registry [18]. Survival trends could be shown through
comparing different calendar periods. Statistical tests are
included in this software. Relative rates among different
age groups were tested using H0-H2 equal vs. unequal
hazards tests.
Results
Observed survival and relative survival rates
Table 1 shows OS and RS rates by the survival year. The
one-, three-, five-, ten-, fifteen, twenty, thirty, and forty-year
OS rates of female breast cancer in Qidong during
Table 1 Observed survival (OS) and relative survival (RS)
rates of female breast cancer in Qidong, 1972–2011 (%)
Survival year OS 2*SEOS RS 2*SERS
1 83.61 1.29 84.76 1.31
2 74.12 1.55 76.22 1.59
3 67.53 1.68 70.45 1.75
4 62.41 1.76 66.06 1.87
5 58.75 1.81 63.12 1.95
6 56.04 1.85 61.16 2.02
7 53.20 1.89 59.00 2.09
8 51.58 1.91 58.18 2.16
9 50.07 1.93 57.49 2.22
10 48.56 1.96 56.81 2.29
11 47.35 1.98 56.49 2.36
12 45.71 2.01 55.64 2.44
13 45.06 2.02 55.98 2.51
14 43.75 2.05 55.53 2.60
15 42.57 2.08 55.26 2.70
16 41.48 2.10 55.11 2.80
17 40.49 2.13 55.10 2.90
18 39.53 2.16 55.16 3.01
19 39.26 2.17 56.22 3.10
20 38.30 2.20 56.36 3.23
21 37.35 2.23 56.58 3.38
22 36.63 2.26 57.23 3.54
23 36.38 2.28 58.69 3.67
24 35.27 2.34 58.86 3.90
25 34.20 2.40 59.15 4.16
26 33.85 2.43 60.80 4.36
27 32.89 2.51 61.49 4.69
28 31.18 2.65 60.85 5.18
29 30.24 2.73 61.77 5.59
30 29.19 2.83 62.59 6.07
31 29.19 2.83 65.82 6.39
32 27.54 3.03 65.42 7.20
33 26.41 3.18 66.47 8.00
34 25.95 3.26 69.66 8.74
35 24.16 3.63 69.47 10.43
36 24.16 3.63 74.70 11.22
37 23.23 3.94 77.82 13.19
38 20.96 4.68 76.35 17.04
39 19.35 5.31 76.90 21.12
40 19.35 5.31 84.00 23.07
2*SEOS, Twice standard error of OS; 2*SERS, Twice standard error of RS.
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42.57%, 38.30%, 29.19%, and 19.35%, while the RS
rates were 84.76%, 70.45%, 63.12%, 56.81%, 55.26%,
56.36%, 62.59%, and 84.00%, respectively. Figure 1 indicates
OS and RS trends of female breast cancer in Qidong
during 1972–2011 by the survival year. Significant
disparities between OS and RS rates could be found in
female breast cancer patients surviving over 10 years. For
survivors more than 20 years after diagnosis, RS rates
increased with the survival year, implying that these
women with breast cancer have a relatively higher survival
chance compared to the general population with the same
demographical characteristics.
Survival rate by age group
Table 2 shows the 5-, and 10-year OS and RS rates by
age group. The 5-year OS rates of age groups 15–34,
35–44, 45–54, 55–64, 65–74, and 75+ were 59.81%,
67.42%, 66.26%, 53.44%, 47.82%, and 30.42%, while the
10-year OS rates were 53.36%, 57.82%, 58.09%, 42.11%,
32.05%, and 14.78%, respectively. The 5-year RS rates were
60.17% 68.27%, 67.79%, 56.03%, 55.50%, and 55.28%, and
10-year RS rates were 54.16%, 59.59%, 61.34%, 47.78%,
51.30%, 59.28%, respectively. The patients at 35–44 or
45–54 years of age experienced higher 5-, and 10-year OS
and RS rates. Statistical differences could be found among
the different age groups (RS: χ2 = 152.15, P = 0.000).
Survival rate by period
Table 3 shows the RS rates by survival year and by period.
An increasing trend for the RS rates of female breast
cancer could be observed through the nine intervals
during 1972–2011 period. Remarkable improvement
could be seen for the 5-year RS rates of 52.08% in 1972
to that of 69.26% in 2003–2007, and for the 10-year
RS rates of 43.16% in 1972 to that of 60.85% in
1998–2002. Little improvement was observed for the
1-year RS rate from 87.91% in 1972 to 90.30% in
2008–2011, and for the 15-year RS from 45.81% in
1972 to 48.22% in 1993–1997.
Discussion
This study provides survival estimates of female patients
diagnosed with breast cancer in Qidong, China from
1972 through 2011. We compare the results available
from other countries or areas. For example, reports from
Korea, Japan, United States, and Germany have shown
better relative survival rates of female breast cancer than
observed in Qidong. The 5-year RS rate (63.12% in
1972–2011) of female breast cancer in Qidong was lower
than those in Korea (79.6% in 1993–1997, 85.0% in
1998–2002) [19], Japan (84.6% in 1993–1996) [20],
United States (89.0% in 1996–2002) [21], Germany
(80.6% in 2000–2002) [22], and most of other Asia cities
Figure 1 Trends for the observed survival (OS) and relative survival (RS) rates of female breast cancer in Qidong, China, 1972–2011.
(−Ο−) OS; (−Δ−) RS.
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of Kampala, Uganda (45.4% in 1993–1997) [24], and
Mumbai, India (46.2% in 1992–1994) [25]. As Bradley
et al. [26] have reported, there are disparities in cancer
survival between subjects enrolled in Medicaid and
subjects not enrolled in Medicaid, a health insurance
program in the United States. Verdecchia et al. [27]
indicated that the most direct way for poorer European
countries to improve all-cancer survival would be to
get richer; for richer countries investment in health
technology is important. Hayat et al. [21] suggested
these disparities may reflect variations in the prevalence of
risk factors, the use of screening tests for early detection,
access to health care services, and/or social and demo-
graphic factors. In a comparative study of Stockholm and
Singapore women with breast cancer, there appear to be
differences in the 5-year OS rates of 72% vs. 64%,
and 5-year RS rates of 80% vs. 70%, respectively. In
Qidong, the data highlight an improvement in prognosis
over the calendar periods, which were likely influenced by
marked economic improvement leading to better medicalTable 2 Five and ten year OS and RS rates of female
breast cancer by age-group in Qidong, 1972–2011 (%)
Age group 15-34 35- 44 45-54 55-64 65-74 75+ Total
5-year OS 59.81 67.42 66.26 53.44 47.82 30.42 58.75
RS 60.17 68.27 67.79 56.03 55.50 55.28 63.12
10-year OS 53.36 57.82 58.09 42.11 32.05 14.78 48.56
RS 54.16 59.59 61.34 47.78 51.30 59.28 56.81
OS, Observed survival; RS, Relative survival.facilities and management of patients from diagnosis
through treatment, as well as improved treatment options
[28]. At the molecular level, Guo et al. [29] reported that
the 5-year survival in female patients with ERα (estrogen
receptor α +) is higher than that with ERα (−) in Chinese
women.
But no matter how poor the survival shown in this
series, compared to results from other parts of the world
or from big cities in China, the data indicate that
survival rates for breast cancer patients over this 40 year
period in Qidong have been improving. Significant
upward trends for the 5-year RS rate were observed,
increasing from 52.08% in 1972 to 69.26% in 2003–2007,
and the 10-year RS rates from 43.16% in 1972 to 60.85%
in 1998–2002. The improvement in survival rate between
1972 and 2011 may be attributed to social and economic
development, as well as improvement in early detection,
such as by increasing the use of mammography, and
therapy [30]. Patients also received better quality care,
as shown in a pay-for-performance program for breast
cancer care in Taiwan [31]. Last century, however,
breast cancer screening programs were almost nonexistent
in Qidong. It seems reasonable to assume that many of
these patients had no chance to receive early detection for
the diagnosis of this cancer, and hence, effective treatment
was rarely possible. In recently years, screening as well as
substantive improvements in diagnosis and treatment
have become possible, through which breast cancers could
be detected at earlier stages and perhaps more suitable
treatment options could be obtained, in turn resulting in
improvements in prognosis.
Table 3 Relative survival rate of female breast cancer by period in Qidong, 1972–2011 (%)
Survival year 1972 1973-1977 1978-1982 1983-1987 1988-1992 1993-1997 1998-2002 2003-2007 2008-2011
1 87.91 85.54 83.28 84.38 85.77 77.02 82.90 85.19 90.30
2 73.74 73.66 72.86 73.98 73.73 69.92 74.30 79.47 85.06
3 64.39 63.54 66.27 68.35 67.92 63.17 68.72 75.89 81.55
4 58.35 58.85 62.71 61.85 62.57 58.51 65.18 73.06 75.71
5 52.08 56.30 60.43 59.98 60.32 54.62 63.11 69.26 -
6 52.90 54.16 59.07 58.09 57.16 52.64 61.68 67.44
7 48.15 51.51 56.24 55.79 54.53 51.15 60.49 65.70
8 47.05 49.72 52.37 55.24 53.99 50.82 61.16 64.38
9 44.17 49.89 50.33 52.50 54.08 50.47 61.45 65.27
10 43.16 51.13 50.24 50.82 52.92 49.76 60.85 -
11 43.99 51.93 50.14 50.62 52.41 48.70 60.46
12 44.93 49.55 51.10 48.86 51.84 48.32 59.38
13 45.87 49.81 51.02 48.63 52.23 48.97 60.30
14 44.79 50.03 49.88 48.01 51.93 48.67 61.22
15 45.81 49.04 50.97 47.83 51.25 48.22 -
16 44.67 46.78 49.83 48.10 52.35 48.82
17 45.82 46.86 49.85 47.91 52.81 47.47
18 47.05 45.02 49.28 48.11 53.74 48.77
19 45.76 46.38 50.60 48.80 54.77 50.05
20 42.02 45.83 50.77 49.04 55.89 -
21 43.31 43.18 51.66 49.30 57.65
22 44.70 41.10 53.21 50.15 59.66
23 43.43 42.62 54.17 51.62 62.06
24 42.07 41.20 55.22 52.19 64.92
25 40.72 42.18 54.83 52.69 -
26 39.31 44.10 56.66 53.66
27 37.86 44.40 57.18 55.70
28 36.23 45.61 55.41 54.98
29 38.07 44.93 56.99 57.12
30 32.84 46.17 58.68 -
31 34.71 48.56 61.57
32 36.29 46.81 62.74
33 38.08 47.39 63.33
34 40.38 49.38 67.23
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of female patients with breast cancer survived 5 years or
more, with a 5-year RS rate of 63.12% (2*SE: 1.95%).
Statistical differences were noted among the differentage groups. Higher 5-, 10-year RS rates were observed
from the groups of age 35–54 years in our series, which
is consistent with a report from a rural area in China
by Chen and his colleagues [32]. Ballard-Barbash
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that physical activity is associated with a reduction in
breast cancer–specific mortality as well as all-cause
mortality; and there is evidence for a dose–response
effect of decreasing mortality risk with increasing
activity in roughly half of the 27 reported observational
studies. This association may be one of the reasons that
younger patients had better survival in our series. Besides
a variety of known factors including tumor size, nodal
status and grade, histological type, improved treatment
modalities and screening, and racial differences [34,35],
there may be other factors that affect the prognosis of
breast cancer, although their mechanisms are unclear. In a
meta-analysis which included 43 studies of women
diagnosed with breast cancer between 1963 and 2005,
Protani et al. [36] illustrated that women with breast
cancer who were obese, had poorer survival than women
with breast cancer who were not obese, with a HR of
1.33 (95% CI: 1.21-1.47). Some suggest [37] that
weight management is a key to controlling prevalent
co-morbid conditions in breast cancer patients, although
it is currently unknown whether post-diagnosis weight
loss can improve prognosis and disease-free survival.
Stage is often considered to be the most important
factor determining survival [28]. Hayat et al. [21] reported
that the 5-year relative survival for those diagnosed at
early stage (stage I) is very good (100% for all races com-
bined), but if metastatic disease is diagnosed (stage IV),
survival drops to 21% for all races combined. A study in
a Finnish population comparing screening-detected
and non-screening-detected breast cancer found that
breast cancer detected by mammography screening is an
independent prognostic factor in breast cancer that is
associated with a more favorable survival rate: a 15-year
survival of 86% for patients screening-detected vs. 68% for
patients diagnosed by other methods [38]. Unfortunately,
for our population-based cancer registration series, one
limitation of our study was that stage information was
available sporadically, a common problem in population-
based cancer registries worldwide [39]. This limitation
does not hinder the assessment of the general evolution of
better survival from breast cancer in this area. We believe,
as the literature [35] has suggested, that disparities in
access and quality of care may be eliminated by under-
standing and addressing cultural and economic barriers.
Conclusions
The survival outcomes in women with breast cancer in
Qidong, China have shown gradual progress during the
past 40 years. There remain disparities of survival rates
of female breast cancer comparing Qidong to more
developed regions, yet the gaps are getting narrower,
and there is continuing opportunity for improving breast
cancer survival in Qidong.Abbreviations
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